Search results
Results from the WOW.Com Content Network
Every U.S. household may place an order to receive four free COVID-19 rapid tests delivered directly to your home, according to the Centers for Disease Control and Prevention.
COVID-19 cases are dropping throughout the country after a summer wave peaked in early August. The percentage of positive COVID-19 tests dropped from 17.8% the week of Aug. 10 to 14.9% the week of ...
In addition to our top pick, the Flowflex COVID-19 Antigen Home Test, the On/Go COVID-19 antigen home test was also approved by the FDA for a 24-month shelf life. Pros Results ready in 15 minutes
In the United States, remdesivir is indicated for the treatment of COVID‑19 in people 28 days of age and older and weighing at least 3 kilograms (6.6 lb) who are hospitalized; or not hospitalized and have mild-to-moderate COVID‑19, and are at high risk for progression to severe COVID‑19, including hospitalization or death. [12] [26]
SARS-CoV-2 is the seventh known coronavirus to infect people, after 229E, NL63, OC43, HKU1, MERS-CoV, and the original SARS-CoV. [105] Like the SARS-related coronavirus implicated in the 2003 SARS outbreak, SARS‑CoV‑2 is a member of the subgenus Sarbecovirus (beta-CoV lineage B). [106] [107] Coronaviruses undergo frequent recombination. [108]
The authors came to the conclusion that no further trials of hydroxychloroquine or chloroquine for treatment of COVID-19 should be carried out. [58] On 26 April 2021, in its amended clinical management protocol for COVID-19, the Indian Ministry of Health lists hydroxychloroquine for use in patients during the early course of the disease. [23]
Any FDA-approved COVID-19 take-home test kits purchased at local pharmacies and retailers after Jan. 15 are eligible for insurance reimbursement, according to the Biden administration.
Ensitrelvir has been investigated for use as potential post-exposure prophylaxis (PEP) for SARS-CoV-2 infection. [20] [21] The SCORPIO-PEP trial, a global Phase 3 study, assessed the safety and efficacy of ensitrelvir in preventing symptomatic COVID-19 among household contacts of individuals with confirmed SARS-CoV-2 infection.